Published in Cellular and Molecular Gastroenterology and Hepatology, the De Sepulveda team's study demonstrates that the MAN2A1-FER oncoprotein, present in several cancers, lacks kinase activity, calling into question the efficacy of tyrosine kinase inhibitors as a therapeutic strategy.